Effective quality management practices in routine clinical next-generation sequencing

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 5, 2016, Pages 761-771

  De Abreu, Francine B ^a   Peterson, Jason D ^a   Amos, Christopher I ^b   Wells, Wendy A ^a   Tsongalis, Gregory J ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

massively parallel sequencing; next generation sequencing; solid tumor; somatic variant

Indexed keywords

GENOMIC DNA; DNA;

AMPLICON; ARTICLE; BREAST CARCINOMA; CANCER SURGERY; CLINICAL LABORATORY; CLINICAL PRACTICE; COLON ADENOCARCINOMA; CYTOLOGY; DNA DETERMINATION; DNA EXTRACTION; GENE FREQUENCY; GLIOBLASTOMA; GLIOMA; GOOD LABORATORY PRACTICE; HUMAN; HUMAN TISSUE; INDEL MUTATION; MELANOMA; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PATIENT CARE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOLID TUMOR; SOMATIC MUTATION; TOTAL QUALITY MANAGEMENT; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; GENETICS; HIGH THROUGHPUT SEQUENCING; LABORATORY TEST; NEOPLASMS; NUCLEOTIDE SEQUENCE; STANDARDS; TISSUE FIXATION;

BASE SEQUENCE; CLINICAL LABORATORY TECHNIQUES; DNA, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; POLYMERASE CHAIN REACTION; TISSUE FIXATION;

EID: 84966606375     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-1190     Document Type: Article

References (23)

1. Ross JS, Cronin M. Whole cancer genome sequencing by nextgeneration methods. Am J Clin Pathol 2011;136:527-39.
2. Yu B, O'Toole SA, Trent RJ. Somatic DNA mutation analysis in targeted therapy of solid tumours. Transl Pediatr 2015;4:125-38.
3. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al. ACMG clinical laboratory standards for nextgeneration sequencing. Genet Med 2013;15:733-47.
4. Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, et al. College of American pathologists' laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med 2015;139:481-93.
5. Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, Strausbaugh LD, et al. Routine use of the ion torrent AmpliSeqTM Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med 2013;13:1-8.
6. Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol 2014;27:314-27.
7. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014;20:682-8.
8. Gailey MP, Stence AA, Jensen CS, Ma D. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue. Cancer Cytopathol 2015;123:30-9.
9. Dumur CI. Available resources and challenges for the clinical annotation of somatic variations. Cancer Cytopathol 2014;122:730-6.
10. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen-the clinical genome resource. N Engl J Med 2015;372:2235-42.
11. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 2014;19:616-22.
12. Janne PA, Smith I, McWalter G, Mann J, Doughrty B, Walker J, et al. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. Br J Cancer 2015;113:199-203.
13. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, et al. On the road to precision cancer medicine: analysis of genomic biomarker actionability in 439 patients. Mol Cancer Ther 2015;14:1488-94.
14. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, et al. Molecular tumor board: the University of California San Diego moores cancer center experience. Oncologist 2014;19:631-6.
15. Tafe LJ, Gorlov I, de Abreu FB, Lefferts JA, Liu X, Pettus JR, et al. Implementation of a Molecular tumor board: the impact on treatment decisions for the first 35 patients evaluated at Dartmouth-Hitchcock Medical Center. Oncologist 2015;20:1011-8.
16. Burrel RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-45.
17. Burrel RA, Swanton C. Tumor heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014;8:1095-111.
18. Pribluda A, de la Cruz CC, Jackson EL. Intratumoral heterogeneity: from diversity comes resistance. Clin Cancer Res 2015;21:2916-22.
19. Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implication of tumor heterogeneity. Clin Cancer Res 2015;21:1258-66.
20. Swanton C. Cancer evolution: the final frontier of precision medicine? Ann Oncol 2014;25:549-51.
21. Janku F. Tumor heterogeneity in the clinic: is it a real problem? Ther Adv Med Oncol 2014;6:43-51.
22. Jorgensen JT. Clinical application of companion diagnostics. Trends Mol Med 2015;21:405-7.
23. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, et al. Clinical utility of patient derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol 2015;33:2472-80.